摘要
目的观察低分子肝素(商品名:海普宁)、葛根素联合治疗急性脑梗死的有效性及安全性。方法70例急性脑梗死患者,随机分为海普宁、葛根素治疗组35例;对照组35例,疗程14天。观察并比较两组患者临床疗效,用药期间的副作用以及随访3个月后患者的死亡、残疾情况。结果海普宁、葛根素组临床总显效率明显优于对照组(P<0.01),随访三个月患者的死亡及残疾率在海普宁、葛根素组有下降的趋势但与对照组比较无统计学意义。结论海普宁、葛根素治疗急性脑梗死安全、有效。
Objective To observe the efficacy and salty of low molecular weight heparin （Hiparin） and Puerarin on acute cerebral infarction. Methods 70 cases of acute cerebral infarction were randomly divided into Hiparin and Puerarin group with 35 cases and the control group with 35 cases. The duration of treatment was 14 days. The curative effects before and after the treatment were compared. The death and disability rate were observed 3 month later and the adverse reaction of Hiparin and Puerarin groups during the treatment were recorded. Results The total evidently effective rate of Hiparin and Puerarin group were significantly higher than those of control group. There were no significant trends in favor of Hiparin and Puerarin in death or disability at follow-up 3 months. Conclusion Hiparin and Puerarin in the treatment of acute cerebral infarction were safe and effective.
出处
《基层医学论坛》
2005年第12期1069-1070,共2页
The Medical Forum
